
Tom Powles/X
Aug 13, 2025, 20:15
Tom Powles: Opening a New Area for Cis-Ineligible MIBC
Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“The +ve perioperative EVP trial for OS in cis ineligible MIBC may open a new area.
Especially if it’s like EVP in M1 disease. 3 more trials in this area are awaited, which test
- EVP vs cisplatin (NIAGARA population),
- EV/PD1/CTLA4 vs surgery
- treatment based on ctDNA status.”
More posts featuring Tom Powles.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 22:37
Sep 2, 2025, 22:03
Sep 2, 2025, 20:50
Sep 2, 2025, 18:53
Sep 2, 2025, 16:54